Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

… Aguirre, Nawwar Al-Attar, Eduardo Alegria, Felicita Andreotti, Werner Benzer, Ole Breithardt,
Nicholas Danchin, Carlo Di Mario, Dariusz Dudek, Dietrich Gulba, Sigrun Halvorsen, …

Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and …

… Jarle Jortveit, Ragna Elise Støre Govatsmark, Tormod Aarlott Digre, Cecilie Risøe, Torstein
Hole, Jan Mannsverk, Stig Arild Slørdahl, Sigrun Halvorsen Om forfatterne … Sigrun Halvorsen …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Surveys and registries are needed to verify that real-life daily practice is in keeping with
what is recommended in the guidelines, thus completing the loop between clinical research, …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

Background It is not known whether prehospital fibrinolysis, coupled with timely coronary
angiography, provides a clinical outcome similar to that with primary percutaneous coronary …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare burden …

In 2014, a joint consensus document dealing with the management of antithrombotic
therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …